| 摘要 |
PROBLEM TO BE SOLVED: To provide a new compound having affinity to 5-HT1A and/orα1 and/orα2 and/or D2 receptor and having utility in the treatment of central nervous system disorders, and to provide a pharmaceutical composition comprising the compound. SOLUTION: The invention relates to a compound represented by formula I, and a pharmaceutical composition comprising the compound (in the formula, Ar represents phenyl, pyridyl, pyrimidinyl, naphthyl, 1,4-benzodioxin-5-yl, 1,4-benzodioxan-5-yl, benzo[b]furan-7-yl, 2,3-dihydrobenzo[b]furan-7-yl, benzo[b]thiophen-7-yl, 2,3-dihydrobenzo[b]thiophen-7-yl or chroman-8-yl, etc., HET represents a substituted pyrazole, imidazole or 1,2,4-triazole, etc., A represents a 1-6C alkylene chain optionally substituted with one or two alkyl groups each having 1-3 carbon atoms). COPYRIGHT: (C)2008,JPO&INPIT
|
